Aberrant activation of the mammalian Target of Rapamycin (mTOR) pathway has been linked to obesity and endocrine therapy resistance, factors that may contribute to Black-White disparities in breast cancer outcomes. This evidence concerns the gene MTOR and obesity due to melanocortin 4 receptor deficiency.